Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorda Therapeutics Inc.

www.acorda.com

Latest From Acorda Therapeutics Inc.

Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
Europe Approvals

GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls

Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.
Europe Approvals

US ‘Blocking-Patent’ Doctrine Comes Under Attack

A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.
Intellectual Property United States

Kyowa Kirin Presses On With Parkinson's Prospect In US As Successor Readied

Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.

United States Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register